| scholarly article | Q13442814 |
| P356 | DOI | 10.3109/08923973.2015.1125917 |
| P698 | PubMed publication ID | 26769136 |
| P2093 | author name string | Åsa Andersson | |
| Samra Sardar | |||
| P2860 | cites work | The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells | Q21195261 |
| Blockade of collagen-induced arthritis post-onset by antibody to granulocyte-macrophage colony-stimulating factor (GM-CSF): requirement for GM-CSF in the effector phase of disease | Q24799657 | ||
| Joint disease caused by defective gp130-mediated STAT signaling. | Q24806131 | ||
| Autoimmune priming, tissue attack and chronic inflammation - the three stages of rheumatoid arthritis | Q27027441 | ||
| Discovery of 4-(5-(cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-N-propylpyrrolo[1,2-f][1,2,4]triazine-6-carboxamide (BMS-582949), a clinical p38α MAP kinase inhibitor for the treatment of inflammatory diseases | Q27664223 | ||
| Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis | Q27691388 | ||
| Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune Diseases | Q27701703 | ||
| Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: preclinical analysis of efficacy and selectivity | Q28293265 | ||
| Cytokines in the pathogenesis of rheumatoid arthritis | Q28303865 | ||
| RN486, a selective Bruton's tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents | Q28567706 | ||
| Anti-inflammatory properties of a novel peptide interleukin 1 receptor antagonist | Q28659160 | ||
| Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation | Q29614224 | ||
| Efficacy of sustained blood levels of interleukin-1 receptor antagonist in animal models of arthritis: comparison of efficacy in animal models with human clinical data | Q30560117 | ||
| Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases | Q33180616 | ||
| On the role of tumor necrosis factor and receptors in models of multiorgan failure, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease | Q33333935 | ||
| KR-003048, a potent, orally active inhibitor of p38 mitogen-activated protein kinase | Q33390326 | ||
| The value of animal models in predicting genetic susceptibility to complex diseases such as rheumatoid arthritis | Q33458893 | ||
| Effects of cyclosporin on collagen induced arthritis in mice | Q33556563 | ||
| Inhibitory effects of anti-inflammatory drugs on type II collagen induced arthritis in rats | Q33557587 | ||
| A novel human anti-interleukin-1β neutralizing monoclonal antibody showing in vivo efficacy | Q33573612 | ||
| Role of tumour necrosis factor alpha in experimental arthritis: separate activity of interleukin 1beta in chronicity and cartilage destruction | Q33782333 | ||
| Discovery of 6-(2,4-difluorophenoxy)-2-[3-hydroxy-1-(2-hydroxyethyl)propylamino]-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (pamapimod) and 6-(2,4-difluorophenoxy)-8-methyl-2-(tetrahydro-2H-pyran-4-ylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (R1487) as o | Q33837251 | ||
| From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins | Q33860728 | ||
| Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? | Q33937489 | ||
| Anti-interleukin 6 receptor antibody treatment in rheumatic disease | Q34071253 | ||
| Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial | Q34092311 | ||
| Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy | Q34092469 | ||
| LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study | Q34096856 | ||
| Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study | Q34187345 | ||
| Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis | Q34317197 | ||
| Targeting interleukin-6 in inflammatory autoimmune diseases and cancers | Q34373967 | ||
| One-year efficacy and safety results of secukinumab in patients with rheumatoid arthritis: phase II, dose-finding, double-blind, randomized, placebo-controlled study | Q34398108 | ||
| Spleen tyrosine kinase inhibitors for rheumatoid arthritis: where are we now? | Q34409073 | ||
| Mavrilimumab: an evidence based review of its potential in the treatment of rheumatoid arthritis | Q34411088 | ||
| Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study | Q34465354 | ||
| Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial | Q34530459 | ||
| Thymus-dependent and -independent regulation of Ia antigen expression in situ by cells in the synovium of rats with streptococcal cell wall-induced arthritis. Differences in site and intensity of expression in euthymic, athymic, and cyclosporin A-tr | Q34567361 | ||
| VX-509 (decernotinib) is a potent and selective janus kinase 3 inhibitor that attenuates inflammation in animal models of autoimmune disease | Q41241144 | ||
| Efficacy and Safety of Anti-Interleukin-20 Monoclonal Antibody in Patients With Rheumatoid Arthritis: A Randomized Phase IIa Trial. | Q41468717 | ||
| Influence of gold salts on adjuvant arthritis in the rat | Q41482555 | ||
| A randomized, double-blind, placebo-controlled, twelve-week, dose-ranging study of decernotinib, an oral selective JAK-3 inhibitor, as monotherapy in patients with active rheumatoid arthritis | Q41668753 | ||
| B-cell inhibition by cross-linking CD79b is superior to B-cell depletion with anti-CD20 antibodies in treating murine collagen-induced arthritis | Q41730840 | ||
| Methotrexate in rheumatoid arthritis: studies with animal models | Q41895010 | ||
| Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies | Q42651946 | ||
| Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis | Q42663487 | ||
| The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancer | Q42704069 | ||
| Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases | Q42709589 | ||
| Significant species difference in amide hydrolysis of GDC-0834, a novel potent and selective Bruton's tyrosine kinase inhibitor | Q42730808 | ||
| Antiarthritis effect of a novel Bruton's tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokinetic/pharmacodynamic modeling: relationships between inhibition of BTK phosphorylation and efficacy | Q42741853 | ||
| Targeting interleukin-17 in patients with active rheumatoid arthritis: rationale and clinical potential | Q43098450 | ||
| Leflunomide induces immunosuppression in collagen-induced arthritis rats by upregulating CD4+CD25+ regulatory T cells | Q43174362 | ||
| Adjuvant oils induce arthritis in the DA rat. I. Characterization of the disease and evidence for an immunological involvement | Q43633841 | ||
| FK506 is superior to methotrexate in therapeutic effects on advanced stage of rat adjuvant-induced arthritis | Q43802791 | ||
| Low affinity antibodies against collagen type II are associated with pathology in collagen-induced arthritis in mice | Q43961247 | ||
| Resveratrol modulates murine collagen-induced arthritis by inhibiting Th17 and B-cell function | Q44202397 | ||
| Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks | Q44774931 | ||
| Immunization with glucose-6-phosphate isomerase induces T cell-dependent peripheral polyarthritis in genetically unaltered mice | Q44807490 | ||
| Comparison of anti-arthritic properties of leflunomide with methotrexate and FK506: effect on T cell activation-induced inflammatory cytokine production in vitro and rat adjuvant-induced arthritis | Q45186044 | ||
| Preclinical to clinical translation of tofacitinib, a Janus kinase inhibitor, in rheumatoid arthritis | Q45804006 | ||
| BMS-582949: crystalline form of a p38alpha inhibitor? WO2008079857. | Q45978392 | ||
| The Bcl-2 family antagonist ABT-737 significantly inhibits multiple animal models of autoimmunity. | Q45983884 | ||
| Efficacy and safety of pamapimod in patients with active rheumatoid arthritis receiving stable methotrexate therapy | Q46055998 | ||
| Anti-interleukin-1 and anti-tumor necrosis factor-alpha synergistically inhibit adjuvant arthritis in Lewis rats | Q46186351 | ||
| A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors | Q46483294 | ||
| Tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorates joint swelling in established monkey collagen-induced arthritis. | Q51700112 | ||
| The orally available Btk inhibitor ibrutinib (PCI-32765) protects against osteoclast-mediated bone loss. | Q51768181 | ||
| Essential role of neutrophils in the initiation and progression of a murine model of rheumatoid arthritis. | Q54001255 | ||
| Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group stud | Q54322103 | ||
| Th17 cells, but not Th1 cells, from patients with early rheumatoid arthritis are potent inducers of matrix metalloproteinases and proinflammatory cytokines upon synovial fibroblast interaction, including autocrine interleukin‐17A production | Q54406138 | ||
| SB1578, a novel inhibitor of JAK2, FLT3, and c-Fms for the treatment of rheumatoid arthritis. | Q54485105 | ||
| Effect of cyclophosphamide, hydrocortisone and levamisole on collagen-induced arthritis in rats. | Q54589671 | ||
| Antigen-induced arthritis in mice. I. Induction of arthritis in various strains of mice. | Q54598631 | ||
| Interference with CD28, CD80, CD86 or CD152 in collagen-induced arthritis. Limited role of IFN-gamma in anti-B7-mediated suppression of disease | Q56905044 | ||
| Methotrexate specifically modulates cytokine production by T cells and macrophages in murine collagen-induced arthritis (CIA): a mechanism for methotrexate-mediated immunosuppression | Q57079507 | ||
| Abatacept Limits Breach of Self-Tolerance in a Murine Model of Arthritis via Effects on the Generation of T Follicular Helper Cells | Q57231970 | ||
| Dissecting the contribution of innate and antigen-specific pathways to the breach of self-tolerance observed in a murine model of arthritis | Q57232002 | ||
| Efficacy and safety of mavrilimumab in Japanese subjects with rheumatoid arthritis: Findings from a Phase IIa study | Q58204616 | ||
| Interleukin-1 drives pathogenic Th17 cells during spontaneous arthritis in interleukin-1 receptor antagonist-deficient mice | Q58999443 | ||
| Altered thymic T-cell selection due to a mutation of the ZAP-70 gene causes autoimmune arthritis in mice | Q59069058 | ||
| Discovery of the macrocycle (9E)-15-(2-(pyrrolidin-1-yl)ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14(26),15,17,20,22-nonaene (SB1578), a potent inhibitor of janus kinase 2/fms-like tyrosine kinase- | Q34635897 | ||
| Arthritis induced in rats with nonimmunogenic adjuvants as models for rheumatoid arthritis. | Q34709387 | ||
| Blocking the effects of IL-1 in rheumatoid arthritis protects bone and cartilage. | Q34809992 | ||
| Effect of methotrexate on collagen-induced arthritis assessed by micro-computed tomography and histopathological examination in female rats | Q35161309 | ||
| The TNF-alpha transgenic mouse model of inflammatory arthritis | Q35194786 | ||
| Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial | Q35540009 | ||
| Methotrexate ameliorates T cell dependent autoimmune arthritis and encephalomyelitis but not antibody induced or fibroblast induced arthritis. | Q35555358 | ||
| Proteoglycan-induced arthritis: immune regulation, cellular mechanisms, and genetics | Q35570852 | ||
| Interleukin-6 and chronic inflammation | Q35578869 | ||
| MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial | Q35605418 | ||
| The K/BxN mouse: a model of human inflammatory arthritis. | Q35628266 | ||
| A Novel Small-Molecule Inhibitor Targeting the IL-6 Receptor β Subunit, Glycoprotein 130. | Q35646881 | ||
| The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis | Q35764862 | ||
| The use of anakinra, an interleukin-1 receptor antagonist, in the treatment of rheumatoid arthritis | Q35789088 | ||
| Abatacept decreases disease activity in a absence of CD4(+) T cells in a collagen-induced arthritis model. | Q35986133 | ||
| Anakinra: review of recombinant human interleukin-I receptor antagonist in the treatment of rheumatoid arthritis | Q36095386 | ||
| Macrophage- and neutrophil-dominant arthritis in human IL-1 alpha transgenic mice | Q36166760 | ||
| Interleukin 6 plays a key role in the development of antigen-induced arthritis | Q36172826 | ||
| Defective gp130-mediated signal transducer and activator of transcription (STAT) signaling results in degenerative joint disease, gastrointestinal ulceration, and failure of uterine implantation | Q36369420 | ||
| Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice | Q36375776 | ||
| Interleukin 6 is required for the development of collagen-induced arthritis | Q36400353 | ||
| The genetics of rheumatoid arthritis: risk and protection in different stages of the evolution of RA. | Q36456814 | ||
| Spontaneous development of autoimmune arthritis due to genetic anomaly of T cell signal transduction: Part 1. | Q36483714 | ||
| Mechanisms of disease: Genetic susceptibility and environmental triggers in the development of rheumatoid arthritis | Q36577538 | ||
| New therapies for treatment of rheumatoid arthritis | Q36849874 | ||
| Utility of animal models for identification of potential therapeutics for rheumatoid arthritis | Q37022699 | ||
| Involvement of endogenous tumor necrosis factor alpha and transforming growth factor beta during induction of collagen type II arthritis in mice | Q37147228 | ||
| Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis | Q37253521 | ||
| Distinct contribution of IL-6, TNF-alpha, IL-1, and IL-10 to T cell-mediated spontaneous autoimmune arthritis in mice | Q37286418 | ||
| The determinants of susceptibility/resistance to adjuvant arthritis in rats | Q37350868 | ||
| CP-690550 Treatment Ameliorates Established Disease and Provides Long-Term Therapeutic Effects in an SKG Arthritis Model | Q37420222 | ||
| Pathogenic antibody recognition of cartilage | Q37511818 | ||
| Treatment of rheumatoid arthritis: state of the art 2009. | Q37607063 | ||
| The efficacy and safety of rituximab for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials | Q37754083 | ||
| Hydroxychloroquine: from malaria to autoimmunity | Q37827403 | ||
| Role of spleen tyrosine kinase inhibitors in the management of rheumatoid arthritis | Q37895250 | ||
| Collagen-induced arthritis as an animal model for rheumatoid arthritis: focus on interferon-γ. | Q37929776 | ||
| Collagen-induced arthritis and related animal models: how much of their pathogenesis is auto-immune, how much is auto-inflammatory? | Q37961298 | ||
| Current understanding of rheumatoid arthritis therapy | Q37987351 | ||
| Rheumatoid arthritis: from autoimmunity to synovitis and joint destruction | Q38019239 | ||
| Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis | Q38020461 | ||
| Ibrutinib and novel BTK inhibitors in clinical development | Q38130010 | ||
| Emerging cell and cytokine targets in rheumatoid arthritis | Q38161794 | ||
| The therapeutic potential of anti-interleukin-20 monoclonal antibody | Q38210876 | ||
| Genetic basis of rheumatoid arthritis: a current review | Q38235551 | ||
| The biological and clinical activity of anti-malarial drugs in autoimmune disorders | Q38246847 | ||
| Mechanisms of tissue damage in arthritis | Q38248430 | ||
| Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis | Q38274571 | ||
| Resveratrol and inflammation: Challenges in translating pre-clinical findings to improved patient outcomes | Q38316214 | ||
| Cytokines as therapeutic targets in rheumatoid arthritis and other inflammatory diseases | Q38362062 | ||
| Animal models of rheumatoid arthritis: How informative are they? | Q38396788 | ||
| Rebamipide suppresses collagen-induced arthritis through reciprocal regulation of th17/treg cell differentiation and heme oxygenase 1 induction | Q38438986 | ||
| Rebamipide attenuates autoimmune arthritis severity in SKG mice via regulation of B cell and antibody production | Q38439088 | ||
| The IL-23-IL-17 axis in inflammatory arthritis | Q38439641 | ||
| Subcutaneously administered ofatumumab in rheumatoid arthritis: a phase I/II study of safety, tolerability, pharmacokinetics, and pharmacodynamics | Q38450594 | ||
| CTLA4-Ig modifies dendritic cells from mice with collagen-induced arthritis to increase the CD4+CD25+Foxp3+ regulatory T cell population | Q38493098 | ||
| Anti-arthritic agents: progress and potential | Q38503700 | ||
| Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans | Q39412429 | ||
| Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. | Q39719120 | ||
| Collagen arthritis as a relevant model for rheumatoid arthritis | Q40338367 | ||
| P433 | issue | 1 | |
| P921 | main subject | rheumatoid arthritis | Q187255 |
| P304 | page(s) | 2-13 | |
| P577 | publication date | 2016-01-15 | |
| P1433 | published in | Immunopharmacology and Immunotoxicology | Q4200316 |
| P1476 | title | Old and new therapeutics for Rheumatoid Arthritis: in vivo models and drug development | |
| P478 | volume | 38 |
| Q92511226 | A Novel Phytochemical, DIM, Inhibits Proliferation, Migration, Invasion and TNF-α Induced Inflammatory Cytokine Production of Synovial Fibroblasts From Rheumatoid Arthritis Patients by Targeting MAPK and AKT/mTOR Signal Pathway |
| Q89302987 | Analysis of Polymorphisms in the Mediator Complex Subunit 13-like (Med13L) Gene in the Context of Immune Function and Development of Experimental Arthritis |
| Q33859026 | Animal models of rheumatoid pain: experimental systems and insights. |
| Q33714969 | Automated Quantification of Early Bone Alterations and Pathological Bone Turnover in Experimental Arthritis by in vivo PET/CT Imaging |
| Q55669895 | Kruppel-Like Factor 4 Positively Regulates Autoimmune Arthritis in Mouse Models and Rheumatoid Arthritis in Patients via Modulating Cell Survival and Inflammation Factors of Fibroblast-Like Synoviocyte. |
| Q38633174 | Meniscal Ossicles as micro-CT Imaging Biomarker in a Rodent Model of Antigen-Induced Arthritis: a Synchrotron-Based X-ray Pilot Study |
| Q48630939 | Modulating the immune system through nanotechnology. |
| Q99405810 | Promising targets and drugs in rheumatoid arthritis: a module-based and cumulatively scoring approach |
| Q92354159 | Quantitative Predictive Modelling Approaches to Understanding Rheumatoid Arthritis: A Brief Review |
| Q58770443 | Targeting of Liver Mannan-Binding Lectin-Associated Serine Protease-3 with RNA Interference Ameliorates Disease in a Mouse Model of Rheumatoid Arthritis |
| Q60912321 | The oncoprotein TBX3 is controlling severity in experimental arthritis |
Search more.